uniQure details three-pronged gene therapy trial program – FierceBiotech
FierceBiotech |
uniQure details three-pronged gene therapy trial program
FierceBiotech uniQure plots to initiate a three-pronged clinical trial program next year as key assets from its in-house pipeline and Bristol-Myers Squibb collaboration advance. uniQure aims to move its hemophilia B gene therapy, AMT-060, into a pivotal trial while … |
